Jeff Bezos’s Prometheus raises $12B to build an ‘artificial general engineer’ for the physical world
The new round values the physical AI startup that aims to automate heavy engineering and drug design at $41 billion.
-
-
AI | Biotech & Health | Climate | Crypto | Fintech | Fundraising | Startups
4 days left to save up to $190 on TechCrunch Founder Summit 2026
Four days left to save up to $190 on your pass to TechCrunch Founder Summit 2026 — the ultimate founder bootcamp — before Early Bird rates end on June 26 at 11:59 p.m. PT. Register today.
-
AI | Biotech & Health | Crypto | Fintech | Fundraising | Startups | TC
Early Bird pricing ends tonight for TechCrunch Founder Summit
Save up to $190 on your pass to TechCrunch Founder Summit 2026. Early Bird pricing ends today, at 11:59 p.m. PT, after which rates increase. Register now.
-
AI | Biotech & Health | TC
The fittest founder in the room got cancer. Here’s how he used AI to fight back.
When confronted with cancer, Conno Christou fed everything tied to his regime — blood results, scan data, wearable output, journal entries — into Claude.
-
Anthropic’s Claude Science bets on workflow, not a new model, to win over scientists
Anthropic’s Claude Science is a workbench that gives scientists one environment to do computational research, saving them from the need to bounce between databases, pipelines, and tools.
-
AI | Biotech & Health | Climate | Crypto | Fintech | Fundraising | Media & Entertainment | Robotics | Startups | Transportation
Builders Stage agenda revealed: Practical strategies for scaling startups at TechCrunch Disrupt 2026
The Builders Stage is returning to TechCrunch Disrupt 2026, bringing together 10,000+ founders, startup operators, and investors for practical conversations. and Q&A on what it takes to build and scale successful companies. Register now to save up to $330.
-
Reed Jobs would rather talk about curing cancer than his last name
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs’ words, a huge part of what Yosemite does. “I didn’t expect Yosemite to be moving this fast,” he said.
-
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences.
-
Daniel Ek’s body-scanning startup Neko Health raises another $700M
Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person’s health.
-
Period tracker Stardust shares users’ health data with analytics firm, says new research
One period tracker app tested by the Mozilla Foundation was ‘squeaky clean,’ while another app was seen sharing users’ health data with an analytics company, underscoring vast differences in user privacy among these apps.
